PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter...
Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a commercial-stage...
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
Krystal Biotech Plans to Advance Eyedrop Gene Therapy That Cured Blindness
PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
¢ Net product revenue of $42.1M in 4Q and $50.7M for the year ¢ New England Journal of Medicine publication of the use of B-VEC eyedrop formulation ¢ Reached alignment with FDA to enable...
Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product.
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the œCompany) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023...
¢ FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the œCompany) (NASDAQ: KRYS), a...